Membrane vesicles studied as carcinoma treatment
A paper was published in early access in Tissue and Cell.
A gene-cell preparation by 每日大赛 comprises a patient鈥檚 stem cells specifically modified to synthesize several therapeutic proteins. One protein stimulates the patient鈥檚 immune system against their tumor, and other proteins launch the cell death process. The technology is based on viral peptides and includes simultaneous synthesis of proteins which are then broken down in cells.
鈥淭he comprehensive approach helps widen the spectrum of applications of such medications and increase the efficacy of the therapy due to stem cells鈥� capacity to selectively transport proteins to the tumor,鈥� comments co-author Valeriya Solovyeva, Lead Research Associate of KFU鈥檚 Gene and Cell Technology Lab. 鈥淭he method has been patented in Russian under N 2757502 – Genetic cassette containing codon-optimized nucleotide sequences of genes TRAIL, PTEN and IFN尾-1, and pharmaceutical composition for the treatment of cancer.鈥�
However, the scientists since then went even further and made the method safer thanks to vesicles obtained from genetically modified cells. Vesicles are produced in the body by all the cells and can transport the proteins of their parent cells.
鈥淭he use of vesicles is promising because they are not altered by a tumor. The obtained vesicles are able to transport therapeutic proteins without any risk for the patient and have already proven effective in cases of breast cancer, lung cancer, and colon cancer,鈥� says Albert Rizvanov, Head of Gene and Cell Technology Lab, Director of the Center for Precision and Regenerative Medicine. 鈥淎s it appears, vesicles can also activate immune cells.鈥�
Cytochalasin B-induced membrane vesicles from human mesenchymal stem cells overexpressing TRAIL, PTEN and IFN-尾1 can kill carcinoma cancer cells
Source text: Media Center
Translation: Yury Nurmeev